Verrica Pharmaceuticals Stock Buy Hold or Sell Recommendation
| VRCA Stock | USD 6.90 0.16 2.27% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Verrica Pharmaceuticals is 'Cautious Hold'. Macroaxis provides Verrica Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding VRCA positions. The advice algorithm takes into account all of Verrica Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Verrica Pharmaceuticals' buy or sell advice are summarized below:
Real Value 8.99 | Target Price 12.67 | Hype Value 7.25 | Market Value 6.9 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Verrica Pharmaceuticals given historical horizon and risk tolerance towards Verrica Pharmaceuticals. When Macroaxis issues a 'buy' or 'sell' recommendation for Verrica Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Verrica |
Execute Verrica Pharmaceuticals Buy or Sell Advice
The Verrica recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Verrica Pharmaceuticals. Macroaxis does not own or have any residual interests in Verrica Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Verrica Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | OK | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Verrica Pharmaceuticals Trading Alerts and Improvement Suggestions
| Verrica Pharmaceuticals had very high historical volatility over the last 90 days | |
| Verrica Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 5.12 M. Net Loss for the year was (67 M) with profit before overhead, payroll, taxes, and interest of 8.31 M. | |
| Verrica Pharmaceuticals currently holds about 14.4 M in cash with (38.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.35. | |
| Verrica Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Roughly 40.0% of the company outstanding shares are owned by insiders | |
| Latest headline from finance.yahoo.com: Canadian securities regulators provide update on interim approach to value-referenced crypto assets |
Verrica Pharmaceuticals Returns Distribution Density
The distribution of Verrica Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Verrica Pharmaceuticals' future price movements. The chart of the probability distribution of Verrica Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Verrica Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Verrica Pharmaceuticals returns is essential to provide solid investment advice for Verrica Pharmaceuticals.
| Mean Return | 0.39 | Value At Risk | -7.39 | Potential Upside | 5.30 | Standard Deviation | 3.88 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Verrica Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Verrica Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Verrica Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Verrica Pharmaceuticals backward and forwards among themselves. Verrica Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Verrica Pharmaceuticals' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Miracle Mile Advisors, Inc. | 2023-12-31 | 118.2 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 111.3 K | J. Goldman & Co Lp | 2023-12-31 | 108 K | Bridgeway Capital Management, Llc | 2023-12-31 | 106.8 K | Nuveen Asset Management, Llc | 2023-12-31 | 95 K | Deutsche Bank Ag | 2023-12-31 | 85.6 K | Kornitzer Capital Management Inc | 2023-12-31 | 74.3 K | Balyasny Asset Management Llc | 2023-12-31 | 65.3 K | Bank Of New York Mellon Corp | 2023-12-31 | 55.7 K | Perceptive Advisors Llc | 2023-12-31 | 7.1 M | Venbio Select Advisor Llc | 2023-12-31 | 4 M |
Verrica Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | 27.9M | (1.9M) | 86K | 54.5M | 6.6M | 6.9M | |
| Change In Cash | (1.0M) | 1.4M | 5.1M | 18.5M | 35.3M | 37.0M | |
| Free Cash Flow | (28.1M) | (31.7M) | (28.5M) | (19.0M) | (38.9M) | (37.0M) | |
| Depreciation | 257K | 229K | 472K | 718K | 836K | 877.8K | |
| Capital Expenditures | 682K | 1.5M | 883K | 302K | 362K | 602.1K | |
| Net Income | (28.2M) | (42.7M) | (35.1M) | (24.5M) | (67.0M) | (63.6M) | |
| End Period Cash Flow | 9.2M | 10.7M | 15.8M | 34.3M | 69.5M | 73.0M | |
| Change To Netincome | 3.3M | 10.6M | 7.5M | 6.8M | 7.8M | 4.8M | |
| Other Non Cash Items | (1.1M) | 940K | 1.4M | 1.9M | 1.7M | 1.8M |
Verrica Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Verrica Pharmaceuticals or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Verrica Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Verrica stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.29 | |
β | Beta against NYSE Composite | 2.08 | |
σ | Overall volatility | 3.78 | |
Ir | Information ratio | 0.09 |
Verrica Pharmaceuticals Volatility Alert
Verrica Pharmaceuticals shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Verrica Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Verrica Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Verrica Pharmaceuticals Fundamentals Vs Peers
Comparing Verrica Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Verrica Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Verrica Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Verrica Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Verrica Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Verrica Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Verrica Pharmaceuticals to competition |
| Fundamentals | Verrica Pharmaceuticals | Peer Average |
| Return On Equity | -2.24 | -0.31 |
| Return On Asset | -0.63 | -0.14 |
| Operating Margin | (10.36) % | (5.51) % |
| Current Valuation | 275.44 M | 16.62 B |
| Shares Outstanding | 42.42 M | 571.82 M |
| Shares Owned By Insiders | 39.70 % | 10.09 % |
| Shares Owned By Institutions | 42.50 % | 39.21 % |
| Number Of Shares Shorted | 4.18 M | 4.71 M |
| Price To Book | 14.83 X | 9.51 X |
| Price To Sales | 56.87 X | 11.42 X |
| Revenue | 5.12 M | 9.43 B |
| Gross Profit | 8.31 M | 27.38 B |
| EBITDA | (62.39 M) | 3.9 B |
| Net Income | (67 M) | 570.98 M |
| Cash And Equivalents | 14.4 M | 2.7 B |
| Cash Per Share | 0.35 X | 5.01 X |
| Total Debt | 45.51 M | 5.32 B |
| Debt To Equity | 2.69 % | 48.70 % |
| Current Ratio | 1.25 X | 2.16 X |
| Book Value Per Share | 0.47 X | 1.93 K |
| Cash Flow From Operations | (38.58 M) | 971.22 M |
| Short Ratio | 32.35 X | 4.00 X |
| Earnings Per Share | (1.48) X | 3.12 X |
| Price To Earnings To Growth | 0.03 X | 4.89 X |
| Target Price | 13.0 | |
| Number Of Employees | 100 | 18.84 K |
| Beta | 1.91 | -0.15 |
| Market Capitalization | 299.48 M | 19.03 B |
| Total Asset | 81.6 M | 29.47 B |
| Retained Earnings | (230.45 M) | 9.33 B |
| Working Capital | 60.51 M | 1.48 B |
| Net Asset | 81.6 M |
Note: Acquisition by Paul Manning of 4761904 shares of Verrica Pharmaceuticals at 2.1 subject to Rule 16b-3 [view details]
Verrica Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Verrica . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Verrica Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Verrica Pharmaceuticals? Buying financial instruments such as Verrica Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 3.3M | 2.7M | 13.9M | 14.6M | Total Assets | 80.1M | 44.7M | 81.6M | 62.0M |
Use Investing Ideas to Build Portfolios
In addition to having Verrica Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Advertising Thematic Idea Now
Advertising
Companies specializing in advertising, marketing and advertising services. The Advertising theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Advertising Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Verrica Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Verrica Stock refer to our How to Trade Verrica Stock guide.Note that the Verrica Pharmaceuticals information on this page should be used as a complementary analysis to other Verrica Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for Verrica Stock analysis
When running Verrica Pharmaceuticals' price analysis, check to measure Verrica Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verrica Pharmaceuticals is operating at the current time. Most of Verrica Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Verrica Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verrica Pharmaceuticals' price. Additionally, you may evaluate how the addition of Verrica Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is Verrica Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verrica Pharmaceuticals. If investors know Verrica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verrica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share 0.113 | Quarterly Revenue Growth 28.235 | Return On Assets (0.63) | Return On Equity (2.24) |
The market value of Verrica Pharmaceuticals is measured differently than its book value, which is the value of Verrica that is recorded on the company's balance sheet. Investors also form their own opinion of Verrica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Verrica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verrica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Verrica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verrica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Verrica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verrica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.